For decades, clinicians have recognized that people living with HIV face an increased risk of stroke compared to the general population, a risk that persists even in the era of effective antiretroviral therapy. Yet, the biological underpinnings of this elevated risk have remained elusive, complicated by the interplay of chronic inflammation, immune dysregulation, and coexisting vascular risk factors often prevalent in this patient population. By leveraging advanced proteomic technology, the researchers conducted an in-depth analysis of plasma proteins in HIV-positive individuals who had experienced stroke, revealing distinct protein expression profiles that distinguish them from their HIV-negative counterparts and those without cerebrovascular events.

The research team employed targeted plasma proteomics, a highly sensitive approach enabling the quantification of hundreds of proteins involved in immune signaling, inflammation, and vascular function from patient plasma samples. This technique allowed for an unparalleled resolution in assessing alterations in circulating protein levels, which often serve as both markers and mediators of pathological processes. Their analysis spotlighted the TNFRSF family of proteins as significantly upregulated in the plasma of HIV-infected stroke patients, suggesting their direct involvement in orchestrating the cellular and molecular events culminating in stroke.

Tumor necrosis factor receptor superfamily proteins are integral players in the immune system, mediating critical signaling pathways involved in apoptosis, inflammation, and cellular proliferation. In the context of HIV infection, chronic immune activation is a hallmark feature, and the aberrant expression of TNFRSF members may amplify inflammatory cascades within the vasculature. The study proposes that the dysregulated TNFRSF signaling potentiates endothelial dysfunction, enhances leukocyte recruitment, and disrupts the blood-brain barrier integrity, thereby promoting ischemic injury and stroke occurrence.

Importantly, the study delineates how the interplay between HIV-driven immune responses and vascular biology contributes to an environment conducive to stroke. The researchers elucidated that the form and degree of TNFRSF upregulation correlate with markers of systemic inflammation and coagulation, hinting at a nexus where immune-mediated vascular injury converges with prothrombotic states to precipitate cerebrovascular events. This insight into the molecular choreography offers a comprehensive understanding that bridges virology, immunology, and neurology.

Moreover, these findings carry significant clinical implications. Currently, stroke risk stratification in HIV-positive patients relies predominantly on traditional cardiovascular risk factors, which inadequately capture the nuanced contributions of chronic immune activation. The identification of TNFRSF proteins as central mediators provides an opportunity to develop blood-based biomarkers for early detection of stroke risk, enabling more timely and personalized preventative strategies.

The therapeutic landscape may also witness paradigm shifts based on this research. Targeting the TNFRSF signaling axis could represent a novel therapeutic avenue to mitigate inflammatory and vascular insults in HIV-infected individuals. Small molecule inhibitors, monoclonal antibodies, or biologics designed to modulate TNFRSF activity are potential candidates for reducing stroke incidence or severity in this vulnerable population, warranting further preclinical and clinical investigation.

Advancing the field further, the study underscores the power of proteomics not only as a discovery tool but also as a means to unravel complex disease mechanisms intricately linked to systemic and neurovascular health. By coupling proteomic profiling with clinical phenotyping, researchers illustrated how molecular signatures can refine disease understanding and guide precision medicine initiatives—particularly critical in multifactorial conditions such as HIV-associated stroke.

The methodological rigor of this investigation bolsters the reliability of its conclusions. Plasma samples from well-characterized patient cohorts underwent stringent proteomic analysis complemented by comprehensive immunological and clinical data integration. This multidisciplinary approach ensured that observed protein alterations were contextualized within the broader disease milieu, enhancing interpretability and translational potential.

Furthermore, the study’s revelations hold promise beyond HIV-associated stroke, as TNFRSF-mediated pathways are implicated in numerous inflammatory and neurovascular disorders. The insight gained here could spur exploration of similar mechanisms in other contexts where chronic inflammation drives vascular pathology, potentially inspiring cross-disciplinary therapeutic innovations.

Notably, this research shines a spotlight on the ongoing challenge of managing chronic comorbidities in aging populations living with HIV. As antiretroviral therapies extend lifespan, addressing non-infectious complications such as stroke becomes increasingly urgent. Understanding molecular drivers like TNFRSF proteins could thus inform holistic treatment approaches aimed at improving long-term neurological health outcomes in these patients.

The study’s authors advocate for sustained efforts in longitudinal proteomic monitoring and the incorporation of TNFRSF-focused biomarkers into clinical trials assessing stroke prevention strategies in HIV. Such integrative research paradigms may accelerate the development of effective interventions tailored to the unique pathophysiology observed in HIV-associated cerebrovascular disease.

In summary, this seminal work by Chen and colleagues represents a major stride in elucidating the molecular basis of HIV-associated stroke. By revealing the centrality of upregulated TNFRSF proteins through targeted plasma proteomics, the study not only enriches scientific understanding but also charts a path toward improved diagnosis, risk stratification, and therapeutic targeting of stroke in people living with HIV. The convergence of virology, immunology, and stroke biology embodied in this research exemplifies the transformative potential of cutting-edge proteomic technologies to resolve complex medical challenges.

As the research community continues to decode the intricacies of HIV-related comorbidities, this study stands as a beacon guiding innovative strategies to mitigate cerebrovascular risk and enhance the quality of life for millions worldwide. The integration of molecular insights into clinical practice will be pivotal in confronting the evolving health landscape faced by those infected with HIV in the modern era.

Subject of Research: The molecular mechanisms underlying HIV-associated stroke, focusing on the role of upregulated tumor necrosis factor receptor superfamily (TNFRSF) proteins.

Article Title: Targeted plasma proteomics reveals a central role of upregulated TNFRSF proteins in HIV-associated stroke.

Article References:

Chen, T., Lin, H., Chen, X. et al. Targeted plasma proteomics reveals a central role of upregulated TNFRSF proteins in HIV-associated stroke. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74258-8

Image Credits: AI Generated

A pioneering study from Tulane University, recently published in JCI Insight, unravels part of this complex puzzle, investigating how long-term ART affects gut immune homeostasis and exploring potential nutritional interventions that might alleviate this residual mucosal impairment. Led by Namita Rout, associate professor at the Tulane National Biomedical Research Center, the research employs a sophisticated nonhuman primate model infected with Simian Immunodeficiency Virus (SIV), which closely parallels human HIV infection both clinically and immunologically.

The study reveals that despite the successful suppression of SIV replication through extended ART, key immune functions necessary for intestinal barrier repair remain compromised. Specifically, populations of gamma delta (γδ) T cells and innate lymphoid cells (ILCs) were found to be disrupted in number and function. These immune cell types are instrumental in preserving mucosal integrity, as they orchestrate the secretion of cytokines and growth factors that regulate epithelial regeneration and immune tolerance, establishing a finely tuned equilibrium within the gut microenvironment.

Central to these findings is the impairment of the Aryl Hydrocarbon Receptor (AHR) and RAR-related Orphan Receptor gamma t (RORγt) signaling pathways, which govern the development and activity of γδ T cells and ILCs. The AHR–RORγt axis modulates mucosal immune responses and tissue repair mechanisms, and its dysregulation in ART-treated SIV infection appears to be a linchpin in the failure to restore full gut mucosal health. This molecular insight advances our understanding of persistent intestinal barrier dysfunction despite viral control.

Intriguingly, the research extends beyond elucidation of pathophysiology to experimental dietary modulation. The team administered a broccoli-based supplement, rich in indole compounds, to a subset of SIV-infected primates undergoing ART. Indoles, naturally occurring phytochemicals particularly abundant in cruciferous vegetables such as broccoli and cabbage, are known ligands for the AHR. Over the course of one month, treated animals exhibited biochemical and immunological markers indicative of enhanced gut barrier integrity, including restoration of γδ T cell populations and normalized ILC function.

This dietary intervention suggests that gut immune pathways retain responsiveness to environmental inputs even after prolonged viral suppression. The implication that functional immune restoration can be modulated nutritionally is a paradigm shift, opening potential avenues for adjunct therapies that go beyond antiviral suppression. Nonetheless, the researchers emphasize that this data is preliminary and derived from a limited animal cohort, calling for rigorous clinical evaluation before extrapolating to human HIV treatment paradigms.

The study’s implications resonate deeply within the broader context of HIV medicine. Despite ART’s efficacy in controlling viremia, chronic inflammation remains an ominous problem, underpinning accelerated aging and comorbidity risk in people living with HIV. This persistent immune activation is partly attributed to microbial translocation stemming from damaged gut epithelia. By decoding the specific immune deficits driving epithelial dysfunction, this work provides a rationale for targeted nutritional or pharmacologic strategies designed to recalibrate mucosal immunity and potentially mitigate systemic inflammation.

Mechanistically, the preservation or restoration of γδ T cells and ILC populations may re-establish the homeostatic cytokine milieu, fostering regeneration of tight junction proteins and enhancing mucin production within the intestinal epithelium. Such effects collectively strengthen the mucosal barrier, limiting exposure to microbial products like lipopolysaccharides that trigger systemic immune activation. This study thus bridges a critical gap between molecular immunology and translational nutrition science in HIV care.

Furthermore, these findings emphasize the gut as an immunological sanctuary in HIV and related retroviral infections, where conventional ART does not uniformly revert the complex immune dysregulation caused by chronic infection. This nuanced understanding underscores the need for a multi-disciplinary approach integrating virology, immunology, and nutritional science to holistically address HIV-associated pathologies. It may also provide insights applicable to other chronic inflammatory conditions characterized by intestinal barrier disruption.

Rout and colleagues’ investigation also raises broader questions about the interplay between diet-derived bioactive compounds and mucosal immune regulation. Given the global burden of HIV and the universal accessibility of dietary interventions, understanding the pharmacodynamics of indoles and other phytochemicals in the context of immune recovery is a promising frontier. Rigorous clinical trials are warranted to define dosage, safety, and efficacy parameters, as well as to explore synergistic effects with existing antiretroviral regimens.

In summary, this groundbreaking research elucidates that while ART controls viral replication effectively, it falls short of fully restoring immune-mediated maintenance of the gut barrier. The identification of the AHR–RORγt axis as a key mediator in this process, coupled with evidence that dietary indoles can positively modulate this pathway, positions non-pharmacological approaches as potentially critical components in managing HIV-associated chronic inflammation. Ultimately, these insights offer hope for enhancing the quality of life and long-term health outcomes for millions living with HIV worldwide.

Subject of Research: Gut immune homeostasis and mucosal repair mechanisms in antiretroviral therapy-treated SIV infection.

Article Title: Dietary Indoles Influence the AHR–RORγt Axis and Mucosal Immune Homeostasis in ART-Treated SIV Infection.

News Publication Date: 22-May-2026.

Web References:

• JCI Insight Article DOI

Keywords: HIV, Antiretroviral Therapy, Gut Mucosal Immunity, Chronic Inflammation, Gamma Delta T Cells, Innate Lymphoid Cells, AHR–RORγt Axis, Dietary Indoles, Microbial Translocation, Intestinal Barrier Integrity, SIV Model, Nutritional Immunomodulation.